Brian R. Houck-Loomis

Brian R. Houck-Loomis

Auto-generated profile, based on publicly available information

Brian R. Houck-Loomis

Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2017 in Nature Methods
Verified
Journal Article
Open access
PDF file
MSMarlon Stoeckius
Marlon Stoeckius
CHChristoph Hafemeister
Christoph Hafemeister
WSWilliam Stephenson
William Stephenson
BHBrian Houck-Loomis
Brian Houck-Loomis
PCPratip K Chattopadhyay
Pratip K Chattopadhyay
PSPeter Smibert
Peter Smibert
Using established high-throughput single-cell RNA-seq platforms, CITE-seq combines highly multiplexed, antibody-based protein marker quantification with unbiased transcriptome profiling for thousands of single cells. High-throughput single-cell RNA sequencing has transformed our understanding of complex cell populations, but it does not provide phenotypic information such as cell-surface protein levels. Here, we describe cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), a method in which oligonucleotide-labeled antibodies are used to integrate cellular protein and transcriptome measurements into an efficient, single-cell readout. CITE-seq is compatible with existing single-cell sequencing approaches and scales readily with throughput increases.

19 December 2018 in Genome Biology
Verified
Journal Article
Open access
PDF file
MSMarlon Stoeckius
Marlon Stoeckius
SZShiwei Zheng
Shiwei Zheng
BHBrian Houck-Loomis
Brian Houck-Loomis
SHStephanie Hao
Stephanie Hao
BYBertrand Z. Yeung
Bertrand Z. Yeung
RSRahul Satija
Rahul Satija
Despite rapid developments in single cell sequencing, sample-specific batch effects, detection of cell multiplets, and experimental costs remain outstanding challenges. Here, we introduce Cell Hashing, where oligo-tagged antibodies against ubiquitously expressed surface proteins uniquely label cells from distinct samples, which can be subsequently pooled. By sequencing these tags alongside the cellular transcriptome, we can assign each cell to its original sample, robustly identify cross-sample multiplets, and “super-load” commercial droplet-based systems for significant cost reduction. We validate our approach using a complementary genetic approach and demonstrate how hashing can generalize the benefits of single cell multiplexing to diverse samples and experimental designs.

10 November 2021 in Nature
Verified
Journal Article
Closed access
PDF file
YZYulei Zhao
Yulei Zhao
YMYonina R. Murciano-Goroff
Yonina R. Murciano-Goroff
JXJenny Y. Xue
Jenny Y. Xue
AAAgnes Ang
Agnes Ang
JLJessica Lucas
Jessica Lucas
PLPiro Lito
Piro Lito

12 August 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ECEmiliano Cocco
Emiliano Cocco
ASAlison M. Schram
Alison M. Schram
AKAmanda Kulick
Amanda Kulick
SMSandra Misale
Sandra Misale
HWHelen H. Won
Helen H. Won
MSMaurizio Scaltriti
Maurizio Scaltriti

1 December 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
AQAlvaro Quintanal
Alvaro Quintanal
HTHirokazu Taniguchi
Hirokazu Taniguchi
YZYingqian A. Zhan
Yingqian A. Zhan
MHMaysun M. Hasan
Maysun M. Hasan
SCShweta S. Chavan
Shweta S. Chavan
TSTriparna Sen
Triparna Sen
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer. Significance: The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung. See related commentary by Meador and Lovly, p. 2962. This article is highlighted in the In This Issue feature, p. 2945

18 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABA. Rose Brannon
A. Rose Brannon
GJGowtham Jayakumaran
Gowtham Jayakumaran
MDMonica Diosdado
Monica Diosdado
JPJuber Patel
Juber Patel
ARAnna Razumova
Anna Razumova
RBRyma Benayed
Ryma Benayed
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis of Circulating cfDNA to Examine Somatic Status), an NGS assay for detection of very low frequency somatic alterations in 129 genes. Analytical validation demonstrated 92% sensitivity in de-novo mutation calling down to 0.5% allele frequency and 99% for a priori mutation profiling. To evaluate the performance of MSK-ACCESS, we report results from 681 prospective blood samples that underwent clinical analysis to guide patient management. Somatic alterations are detected in 73% of the samples, 56% of which have clinically actionable alterations. The utilization of matched normal sequencing allows retention of somatic alterations while removing over 10,000 germline and clonal hematopoiesis variants. Our experience illustrates the importance of analyzing matched normal samples when interpreting cfDNA results and highlights the importance of cfDNA as a genomic profiling source for cancer patients.